solian 200 mg tabletter
sanofi a/s - amisulprid - tabletter - 200 mg
solian 200 mg tabletter
2care4 aps - amisulprid - tabletter - 200 mg
solian 200 mg tabletter
paranova danmark a/s - amisulprid - tabletter - 200 mg
solian 200 mg tabletter
orifarm a/s - amisulprid - tabletter - 200 mg
solian 50 mg tabletter
orifarm a/s - amisulprid - tabletter - 50 mg
solian 50 mg tabletter
sanofi a/s - amisulprid - tabletter - 50 mg
solian 50 mg tabletter
2care4 aps - amisulprid - tabletter - 50 mg
solensia
zoetis belgium sa - frunevetmab - analgetika - katte - for the alleviation of pain associated with osteoarthritis in cats.
tepadina
adienne s.r.l. s.u. - thiotepa - hematopoietisk stamcelletransplantation - antineoplastiske midler - i kombination med andre kemoterapeutiske lægemidler:med eller uden total body bestråling (tbi) som konditionering behandling forud for allogen eller autolog hæmatopoietisk stamcelletransplantation (hpct) hæmatologiske sygdomme hos voksne og pædiatriske patienter, når høj-dosis kemoterapi med hpct support er passende til behandling af solide tumorer hos voksne og pædiatriske patienter. det foreslås, at tepadina skal ordineres af læger med erfaring i plejende behandling forud for hæmatopoietisk stamcelletransplantation.
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastiske midler - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.